The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
History of the Discovery and Clinical Introduction of Chlorpromazine
Abstract
BACKGROUND: The historical process of discovery and clinical introduction of chlorpromazine, one of the greatest advances of 20th century medicine and history of psychiatry, is analyzed. METHODS: In this review, we have studied the original works of pioneers in the discovery and clinical use of chlorpromazine, as well as the contributions of prestigious researchers (historians, pharmacologists, psychiatrists, etc.) about this topic. RESULTS: The discovery of phenothiazines, the first family of antipsychotic agents has its origin in the development of German dye industry, at the end of the 19th century (Graebe, Liebermann, Bernthsen). Up to 1940 they were employed as antiseptics, antihelminthics and antimalarials (Ehrlich, Schulemann, Gilman). Finally, in the context of research on antihistaminic substances in France after World War II (Bovet, Halpern, Ducrot) the chlorpromazine was synthesized at Rhône-Poulenc Laboratories (Charpentier, Courvoisier, Koetschet) in December 1950. Its introduction in anaesthesiology, in the antishock area (lytic cocktails) and "artificial hibernation" techniques, is reviewed (Laborit), and its further psychiatric clinical introduction in 1952, with initial discrepancies between the Parisian Val-de-Grâce (Laborit, Hamon, Paraire) and Sainte-Anne (Delay, Deniker) hospital groups. The first North-American publications on chlorpromazine took place in 1954 (Lehmann, Winkelman, Bower). The introduction of chlorpromazine in the USA (SKF) was more difficult due to their strong psychoanalytic tradition. The consolidation of the neuroleptic therapy took place in 1955, thanks to a series of scientific events, which confirmed the antipsychotic efficacy of the chlorpromazine. CONCLUSIONS: The discovery of the antipsychotic properties of chlorpromazine in the 1950s was a fundamental event for the practice of psychiatry and for the genesis of the so-called "psychopharmacological revolution."
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
LITHIUM SALTS IN THE TREATMENT OF PSYCHOTIC EXCITEMENT
Cade, J. F. J. (1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb36912.x · Cited by 1,463
Lithium salts in the treatment of psychotic excitement
Cade, J. F. J. (1999) · Australian and New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.1999.06241.x · Cited by 1,150
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
A Survey of Drug-Induced Extrapyramidal Reactions
Ayd, F. J. (1961) · JAMA · doi:10.1001/jama.1961.03040120016004 · Cited by 753
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602
Osmond, H., & Smythies, J. (1952) · Journal of Mental Science · doi:10.1192/bjp.98.411.309 · Cited by 472
Healy, D. (1998) · DigitalGeorgetown (Georgetown University Library) · Cited by 467
The neuroleptic malignant syndrome
(1980) · Reactions · doi:10.1007/bf03264026 · Cited by 460
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
Phenothiazine Treatment in Acute Schizophrenia: Effectiveness
(1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210028005 · Cited by 334
Guttmacher, M. S. (1964) · PubMed · Cited by 310
Schizophrenia: A New Approach. II. Result of a Year's Research
Hoffer, A., Osmond, H., & Smythies, J. (1954) · Journal of Mental Science · doi:10.1192/bjp.100.418.29 · Cited by 298
A history of antipsychotic drug development
Shen, W. W. (1999) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(99)90082-2 · Cited by 273
Self-citationCHLORPROMAZINE: New Inhibiting Agent for Psychomotor Excitement and Manic States
LEHMANN, H. E. (1954) · A.M.A. Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1954.02320380093011 · Cited by 251
[Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)].
Delay, J., Deniker, P., & Jm, H. (1952) · PubMed · Cited by 244
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
USE OF RAUWOLFIA SERPENTINA BENTH. IN NEUROPSYCHIATRIC CONDITIONS
Kline, N. S. (1954) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1954.tb45922.x · Cited by 193
Schizophrenia: A Follow-up Study of the Results of Five Forms of Treatment
May, P. R. A. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780320056006 · Cited by 166
[A new vegetative stabilizer; 4560 R.P..].
Laborit, H., Huguenard, P., & Alluaume, R. (1952) · PubMed · Cited by 161
The Last Half-Century of Psychiatric Services as Reflected in Psychiatric Services
Geller, J. L. (2000) · Psychiatric Services · doi:10.1176/ps.51.1.41 · Cited by 160
CHLORPROMAZINE IN THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
WINKELMAN, N. W. (1954) · JAMA · doi:10.1001/jama.1954.03690190024007 · Cited by 142
Casey, J. F. (1960) · A M A Archives of General Psychiatry · doi:10.1001/archpsyc.1960.03590080086012 · Cited by 140
The Treatment of Schizophrenia
(1934) · Science · doi:10.1126/science.79.2058.10-t · Cited by 140
[Therapeutic method derived from hiberno-therapy in excitation and agitation states].
Delay, J., Deniker, P., & Jm, H. (1952) · PubMed · Cited by 124
Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic Patients
Elkes, J., & Elkes, C. (1954) · BMJ · doi:10.1136/bmj.2.4887.560 · Cited by 119
TREATMENT OF SCHIZOPHRENIC REACTIONS WITH PHENOTHIAZINE DERIVATIVES
Casey, J. F., Lasky, J. J., Klett, C. J., & Hollister, L. E. (1960) · American Journal of Psychiatry · doi:10.1176/ajp.117.2.97 · Cited by 115
The History of the Psychopharmacology of Schizophrenia
Lehmann, H. E., & Ban, T. A. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200205 · Cited by 109
Pharmacotherapy of mental illness - a historical analysis
Ban, T. A. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00160-9 · Cited by 106
Tonus sympathique, adrénaline et controle réticulaire de la motricité spinale
Dell, P. C., Bonvallet, M., & Hugelin, A. (1954) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(54)90087-5 · Cited by 105
[Artificial hibernation by pharmacodynamical and physical means].
Laborit, H., & Huguenard, P. (1951) · PubMed · Cited by 86
Pharmacodynamic basis for the use of chlorpromazine in psychiatry.
Courvoisier, S. (1956) · PubMed · Cited by 72
[Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments].
Steck, H. (1954) · PubMed · Cited by 57
Hj, H. (1961) · PubMed · Cited by 55
[N-dimethylamino-prophylchlorophenothiazine (4560 RP) therapy of confusional states].
Delay, J., Deniker, P., Harl, & Grasset, A. (1952) · PubMed · Cited by 46
What’s in a name? The evolution of the nomenclature of antipsychotic drugs
King, C., & Voruganti, L. N. P. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0220 · Cited by 43
The early history of psychotherapeutic drugs
Jacobsen, E. (1986) · Psychopharmacology · doi:10.1007/bf00310617 · Cited by 42
Lopez-Munoz, F. J., Álamo, C., Rubio, G., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00165-9 · Cited by 40
Self-citationExtrapyramidal side effects: a historical perspective
Rifkin, A. E. (1988) · Pain · doi:10.1016/0304-3959(88)90243-6 · Cited by 34
Chlorpromazine in Psychiatric Illness
Bower, W. H. (1954) · New England Journal of Medicine · doi:10.1056/nejm195410212511703 · Cited by 26
The Strange Story of Clozapine
McKenna, P. J., & Bailey, P. (1993) · The British Journal of Psychiatry · doi:10.1192/s0007125000131691 · Cited by 22
History of the Development of Antipsychotic Medication
Frankenburg, F. R. (1994) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30098-4 · Cited by 21
[30 years later. The story of the discovery of neuroleptics].
Chertok, L. (1982) · PubMed · Cited by 3
Cited by
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Antimicrobial photodynamic therapy – what we know and what we don’t
Cieplik, F., Deng, D., Crielaard, W., Buchalla, W., Hellwig, E., Al-Ahmad, A., & Maisch, T. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1467876 · Cited by 902
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Lopez-Munoz, F., & Alamo, C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168001 · Cited by 476
Self-citationPhysiological functions of D-amino acid oxidases: from yeast to humans
Pollegioni, L., Piubelli, L., Sacchi, S., Pilone, M. S., & Molla, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6558-4 · Cited by 359
Metadata
- Authors
- López-Muñoz, F., Alamo, C., cuenca, E., Shen, W., Clervoy, P., & Rubio, G.
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2005-07-01
- Volume
- 17
- Issue
- 3
- Pages
- 113-135
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W2125249259
- Cited by
- 354
- References
- 44
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.